Publications
360
Citations
9,285
Est. group size
~2
Recurring co-author estimate
Active years
26
Publishing since 2001
Almut G. Winterstein studies the safety of medications used during pregnancy and in the general population, using large real-world healthcare databases (such as insurance claims data) to detect risks like birth defects and other adverse outcomes. Her work also contributes to developing tools and methods for measuring drug safety and effectiveness, including studies on cannabis, opioids, biologics, and cardiovascular devices.
Publication output has fluctuated but remained fairly steady over the last decade, with a peak around 2021 and continued substantial activity through 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Risk of Fetal Exposure to Teratogenic Medications: Development of Evidence for the Teratogenic Risk Impact and Mitigation (TRIM) Tool
Drug Safety · 2026
- Joint Position Statement from the Society for Birth Defects Research and Prevention, the Organization of Teratology Information Specialists, and the Developmental Neurotoxicology Society: A Call for Implementation of Risk Evaluation and Mitigation Strategies to Reduce Prenatal Exposure to Valproate
Birth Defects Research · 2026
- Neonatal Outcome Ascertainment in Mother‐Infant Paired Claims
Pharmacoepidemiology and Drug Safety · 2026
- A new tool for pregnancy research: a unified definition for major congenital malformation across ICD eras
American Journal of Epidemiology · 2026
- Effectiveness of THC-containing cannabis for inflammatory bowel disease: a systematic review
Journal of Cannabis Research · 2026
- Use of Biologics During Pregnancy Among Patients With Autoimmune Conditions
JAMA Network Open · 2025
- Association Between Use of WATCHMAN Device and 1-Year Mortality Using High-Dimensional Propensity Scores to Reduce Confounding
Circulation Cardiovascular Quality and Outcomes · 2025
- Respiratory Syncytial Virus Incidence in Young Children in the United States: Impact of Methodologies and Patient Characteristics
Influenza and Other Respiratory Viruses · 2025
- Teratogenic Risk Impact Mitigation (TRIM): Development of Explicit Criteria to Facilitate Decisions Regarding Teratogenic Risk Mitigation Strategies
Drug Safety · 2025
- Validation of diagnosis codes for low birth weight and small for gestational age in the Medicaid Analytic eXtract database
American Journal of Epidemiology · 2025
- COVID-19 pandemic impact on clinical condition capture in real-world data: an assessment framework
American Journal of Epidemiology · 2025
- Disparities in Initial Antihypertensive Intensity by Sex, Race and Ethnicity in Newly Treated Patients With Hypertension
American Journal of Hypertension · 2025
- Re: The association between glucose‐dependent insulinotropic polypeptide and/or glucagon‐like peptide‐1 receptor agonist prescriptions and substance‐related outcomes in patients with opioid and alcohol use disorders: A real‐world data analysis
Addiction · 2025
- Author response for "Respiratory Syncytial Virus Incidence in Young Children in the United States: Impact of Methodologies and Patient Characteristics"
2025
- Risk Management of Valproate and Other Teratogenic Anticonvulsants in the Era of Proliferating Use
The Journal of Pediatric Pharmacology and Therapeutics · 2025
- Pharmacoepidemiology and Drug Safety×18
- Medical Cannabis and Cannabinoids×10
- American Journal of Health-System Pharmacy×10
- Drug Safety×9
- JAMA Network Open×8
- Cynthia P. Koh-Knox
Medicine · Purdue University West Lafayette
- Kelsey K. Schmuhl
Medicine · The Ohio State University
- Carol A. Ott
Medicine · Purdue University West Lafayette
- Milap C. Nahata
Medicine · The Ohio State University
- John M. Allen
Medicine · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile